The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The potential of next-generation BCL2 inhibitors in CLL and findings from the BGB-11417-101 study
Piers Patten, MB ChB, MRCP, FRCPath, PhD, King’s College London, London, UK, comments on the potential benefits of next-generation BCL2 inhibitors in the treatment of chronic lymphocytic leukemia (CLL). He highlights the promising initial data from the BGB-11417-101 study (NCT04277637), which shows impressive outcomes of sonrotoclax in combination with zanubrutinib. Dr Patten notes that while overall survival outcomes are yet to be confirmed, the progression-free survival (PFS) curves presented at the meeting are extremely promising. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The obvious next generation BCL2 inhibitor is the compound called sonrotoclax, and that’s been trialled as a single agent in CLL, but also in combination with the second generation agent, zanubrutinib. We’ve only seen initial Phase I data with this combination, but that data was presented again, the 101 study at ASH in 2024. The MRD rates seem to be very impressive, especially for the higher dose of sonrotoclax and especially those after 48 weeks of combined therapy...
The obvious next generation BCL2 inhibitor is the compound called sonrotoclax, and that’s been trialled as a single agent in CLL, but also in combination with the second generation agent, zanubrutinib. We’ve only seen initial Phase I data with this combination, but that data was presented again, the 101 study at ASH in 2024. The MRD rates seem to be very impressive, especially for the higher dose of sonrotoclax and especially those after 48 weeks of combined therapy. We don’t know if that’s going to translate into a prolonged progression-free survival and indeed ultimately overall survival, but the PFS curves which were presented at the meeting are extremely impressive. So I think time will tell whether we’re going to see a clinically relevant difference using these new combinations, but certainly efficacy appears initially very promising and the side effect profile appears extremely attractive. I think therefore these agents will be of particular interest in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Novartis: Research Funding; Janssen: Honoraria, Other: Travel, accommodations, expenses, Research Funding; BeiGene: Honoraria, Other: Travel, accommodations, expenses, Research Funding; AbbVie: Honoraria, Other: Travel, accommodations, expenses, Research Funding; AstraZeneca: Honoraria, Research Funding.
